New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

June 20, 2024

https://www.globenewswire.com/news-release/2024/06/20/2901632/0/en/New-Broad-Spectrum-Antiviral-Currently-in-a-Phase-2a-Clinical-Trial-in-Influenza-A-may-be-Effective-Against-the-H5N1-Avian-Influenza-Strain-Identified-in-Humans-Exposed-to-Infected.html

BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc.’s (Nasdaq:COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies. CC-42344 is a new class of antiviral drugs designed to block essential steps in the replication and transcription of the influenza A virus.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.